title: Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma.
abstract: Renal cell carcinoma (RCC) is the most common malignancy of adult human kidney, which accounts for more than 2 % of all cancers. RCC generally does not respond well to conventional chemotherapy and radiotherapy. Cytokine-induced killer (CIK) cells are ex vivo activated lymphocytes with potent activity against various tumors and minimal side effects. Here, we summarize the data on preclinical and clinical efficacy of CIK cells for RCC treatment. Our preclinical data show that CIK cells have potent anti-tumor activity in vitro and in an in vivo nude mouse xenograft model. Clinical studies for the treatment of RCC patients indicate that CIK cell therapy can induce favorable responses with no serious side effects. These studies suggest that CIK cells may become a valuable strategy for the treatment of patients with RCC.
authors.affiliation: College of Pharmacy, Chungbuk National University, 52 Naesoodong, Heungduk, Cheongju, Chungbuk, 361-763, South Korea.
authors.forename: Ji Sung
authors.initials: JS
authors.lastname: Kim
authors.forename: In Sung
authors.initials: IS
authors.lastname: Chung
authors.forename: Sang Hee
authors.initials: SH
authors.lastname: Lim
authors.forename: Yunsoo
authors.initials: Y
authors.lastname: Park
authors.forename: Mi Jeong
authors.initials: MJ
authors.lastname: Park
authors.forename: Ju Young
authors.initials: JY
authors.lastname: Kim
authors.forename: Yong Guk
authors.initials: YG
authors.lastname: Kim
authors.forename: Jin Tae
authors.initials: JT
authors.lastname: Hong
authors.forename: Youngsoo
authors.initials: Y
authors.lastname: Kim
authors.forename: Sang-Bae
authors.initials: SB
authors.lastname: Han
mesh_terms: D000818:Animals; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D055612:Cytokine-Induced Killer Cells / Q000637:transplantation*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007680:Kidney Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays